Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge Completes $43 Million E Financing for Rare Disease Drugs

publication date: Dec 1, 2020

CANbridge Pharma completed a $43 million Series E financing that is a follow-on to its $98 million Series D round, announced in February. CANbridge is a Beijing company focused on rare diseases. The company said it would use the proceeds to expand its rare disease pipeline through internal development and external partnerships, advance clinical development of pre-clinical stage assets and launch Hunterase®, a treatment for Hunter syndrome. The E round was led by 3W Fund Management and included new investors Casdin Capital, Summer Capital, SPDBI and Yaly Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital